Zhitong Finance App News, Siludi Pharmaceutical Co., Ltd. (01244.HK) announced that its commercial product Enveda® (generic name: Envolizumab injection, original research code: KN035) was officially certified as an orphan drug for gastric cancer and gastroesophageal junction cancer. This is the third orphan drug indication successfully approved by Envida® after being indicated for cholangiocarcinoma and soft tissue sarcoma.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Siludi Pharmaceutical Co., Ltd. (01244.HK) announced that its commercial product Enveda® (generic name: Envolizumab injection, original research code: KN035) was officially certified as an orphan drug for gastric cancer and gastroesophageal junction cancer. This is the third orphan drug indication successfully approved by Envida® after being indicated for cholangiocarcinoma and soft tissue sarcoma.